Investor Relations
|
GeneNews Limited 2 East Beaver Creek Road, Building 2 Richmond Hill, Ontario, Canada L4B 2N3 Phone: (905) 739-2030 Toll Free: 1-866-375-0442 Fax: (905) 739-2031 E-mail: contact@genenews.com |
Key Statistics Industry: Biotechnology Segment: Genomics Ownership: Public Exchange: TSX Symbol: GEN |
Description
Founded in 1998, GeneNews is a biotechnology company focused on applying the Sentinel Principle® to develop and commercialize novel blood-based molecular diagnostic tests in cancer, cardiovascular disease, central nervous system disorders, psychiatric disorders and arthritis. GeneNews is developing specific diagnostic tests in these areas that address critical unmet clinical needs, while at the same time delivering significant healthcare and economic benefits. The first tests under development are tests for colorectal cancer and prostate cancer. The Sentinel Principle® is a powerful enabling technology for identifying and developing blood-based biomarkers which will eventually lead to the delivery of Personalized Health Management.


